elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
Tyrosine-kinase inhibitor
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Tyrosine-kinase inhibitor
RIS
0.001
(Research Intensity Score)
Papers
37
Top papers
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2023 · 681 citations
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
2020 · 1525 citations
Lung Cancer in Nonsmoking Individuals
2025 · 30 citations
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 · 3383 citations
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
2020 · 280 citations
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
2025 · 17 citations
An aptamer-drug conjugate for promising cancer therapy with comprehensive evaluation from rodents to non-human primates
2025 · 12 citations
Treatment Advances in Tumor-Induced Osteomalacia
2025 · 10 citations
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · 6 citations
Newest papers
Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies
2026 · 2 citations
Nuclear‐Targeted Boron‐Lapatinib Hybrid for Enhanced Boron Neutron Capture Therapy in Advanced Thyroid Carcinoma
2026 · 1 citations
Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST
2026
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)
2026
Clinical efficacy and safety outcomes of anlotinib therapy in sarcoma: a systematic review and meta-analysis
2026
Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges
2026
Food Effects, Pharmacokinetic Drug–Drug Interactions, and Clinical Optimization of Oral Anticancer Agents
2026
Why precision oncology works: lessons from gastrointestinal stromal tumours
2026
A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).
2026
Browse all papers →
Tyrosine-kinase inhibitor's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Tyrosine-kinase inhibitor's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link